JANX Stock Analysis: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$14.51
0.61 (4.39%)
▲
5d:
+5.14%
30d:
+7.96%
90d:
+4.92%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
JANX is down 3.1% this week, but smart money is accumulating calls. Top strike: $17.5 2026-05-15 with 1,024 OI. Call ratio: 66% View Scanner →
Strength: 3.2/10
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: JANX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: JANX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $14.51, which is considered oversold relative to its 30-day fair value range of $13.39 to $14.04.
Technical Outlook: Technically, JANX is in a strong downtrend. The price is approaching resistance at $14.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: JANX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $54.00 (+272.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JANX is in a strong downtrend. The price is approaching resistance at $14.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: JANX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $54.00 (+272.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$13.39 -
$14.04
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 272.2% below Wall St target ($54.00)
Fair Price Analysis
30-Day Fair Range
$13.39 -
$14.04
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$13.02
Resistance Level
$14.68
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.16
Wall Street Target
$54.00
(+272.2%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: April 02, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:29 AM
Data refreshes hourly during market hours. Next update: 8:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew Hollman Meyer
SELL
1879 shares
2026-01-02
Charles M Winter
SELL
2401 shares
2026-01-02
David Alan Campbell
SELL
8072 shares
2026-01-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$134 | 61 BUY |
|
EXEL
Exelixis Inc |
BUY
20 analysts |
$47 | 64 BUY |
